By: Aymon Choudhury, PharmD Candidate c/o 2027 Acute coronary syndrome (ACS) includes three clinical conditions: unstable angina, non-ST-segment elevation myocardial infarction (NSTEMI), and ST-segment elevation myocardial infarction (STEMI). These conditions are a major cause of morbidity and mortality worldwide, requiring rapid diagnosis, timely intervention with reperfusion, guideline-directed drug therapy, coordinated transitions of care between healthcare…

By: Amanda Kastel, PharmD Candidate c/o 2027 On December 22, 2025, the FDA approved the once-daily oral Wegovy® (semaglutide) tablet, making it the first oral GLP-1 receptor agonist approved for weight management. Although Rybelsus® (semaglutide) has been available as an oral GLP-1 tablet since 2019, its FDA-approved indication is limited to the treatment of type…

By: Archana Murugan, PharmD Candidate c/o 2029 Overview Diabetes is a chronic disease caused by insufficient or absent insulin secretion leading to high blood sugar levels in the body. Diabetes is mainly characterized by two types: type 1 and type 2. In type 1, the body makes insufficient or no insulin and the immune system…

By: Michelle Flores, Pharm D Candidate 2027 A large comparative effectiveness study from Denmark has found that sodium-glucose cotransporter-2 inhibitors (SGLT-2is) may offer stronger kidney protection than glucagon-like peptide-1 receptor agonists (GLP-1s) in patients with type 2 diabetes (T2D). Researchers evaluated adults with metformin-treated T2D who began therapy with either an SGLT-2 inhibitor or a…